HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.

AbstractBACKGROUND:
Human immunodeficiency virus (HIV) protease inhibitors show activity against Plasmodium falciparum in vitro. We hypothesized that the incidence of malaria in HIV-infected children would be lower among children receiving lopinavir-ritonavir-based antiretroviral therapy (ART) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART.
METHODS:
We conducted an open-label trial in which HIV-infected children 2 months to 5 years of age who were eligible for ART or were currently receiving NNRTI-based ART were randomly assigned to either lopinavir-ritonavir-based ART or NNRTI-based ART and were followed for 6 months to 2 years. Cases of uncomplicated malaria were treated with artemether-lumefantrine. The primary end point was the incidence of malaria.
RESULTS:
We enrolled 176 children, of whom 170 received the study regimen: 86 received NNRTI-based ART, and 84 lopinavir-ritonavir-based ART. The incidence of malaria was lower among children receiving the lopinavir-ritonavir-based regimen than among those receiving the NNRTI-based regimen (1.32 vs. 2.25 episodes per person-year; incidence-rate ratio, 0.59; 95% confidence interval [CI], 0.36 to 0.97; P=0.04), as was the risk of a recurrence of malaria after treatment with artemether-lumefantrine (28.1% vs. 54.2%; hazard ratio, 0.41; 95% CI, 0.22 to 0.76; P=0.004). The median lumefantrine level on day 7 after treatment for malaria was significantly higher in the lopinavir-ritonavir group than in the NNRTI group. In the lopinavir-ritonavir group, lumefantrine levels exceeding 300 ng per milliliter on day 7 were associated with a reduction of more than 85% in the 63-day risk of recurrent malaria. A greater number of serious adverse events occurred in the lopinavir-ritonavir group than in the NNRTI group (5.6% vs. 2.3%, P=0.16). Pruritus occurred significantly more frequently in the lopinavir-ritonavir group, and elevated alanine aminotransferase levels significantly more frequently in the NNRTI group.
CONCLUSIONS:
Lopinavir-ritonavir-based ART as compared with NNRTI-based ART reduced the incidence of malaria by 41%, with the lower incidence attributable largely to a significant reduction in the recurrence of malaria after treatment with artemether-lumefantrine. Lopinavir-ritonavir-based ART was accompanied by an increase in serious adverse events. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT00978068.).
AuthorsJane Achan, Abel Kakuru, Gloria Ikilezi, Theodore Ruel, Tamara D Clark, Christian Nsanzabana, Edwin Charlebois, Francesca Aweeka, Grant Dorsey, Philip J Rosenthal, Diane Havlir, Moses R Kamya
JournalThe New England journal of medicine (N Engl J Med) Vol. 367 Issue 22 Pg. 2110-8 (Nov 29 2012) ISSN: 1533-4406 [Electronic] United States
PMID23190222 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Anti-Retroviral Agents
  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Drug Combinations
  • Ethanolamines
  • Fluorenes
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • Ritonavir
Topics
  • Anti-Retroviral Agents (therapeutic use)
  • Antimalarials (pharmacokinetics, therapeutic use)
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins (pharmacokinetics, therapeutic use)
  • Child, Preschool
  • Drug Combinations
  • Drug Interactions
  • Drug Therapy, Combination
  • Ethanolamines (pharmacokinetics, therapeutic use)
  • Female
  • Fluorenes (pharmacokinetics, therapeutic use)
  • HIV Infections (drug therapy)
  • HIV Protease Inhibitors (therapeutic use)
  • Humans
  • Incidence
  • Infant
  • Kaplan-Meier Estimate
  • Lopinavir (therapeutic use)
  • Malaria (drug therapy, epidemiology, prevention & control)
  • Male
  • Reverse Transcriptase Inhibitors (therapeutic use)
  • Ritonavir (therapeutic use)
  • Secondary Prevention
  • Uganda

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: